- Classification from $NOVO B (+2.97%) Novo Nordisk by Deutsche Bank Research remains at "Buy"
- Price target unchanged at 750 Danish kroner
- Change of CEO announcement seems arbitrary in terms of timing and content
- A more natural occasion for the announcement would be the publication of the quarterly figures would have been
- Uncertainties exist about:
- criteria for the selection of the new CEO
- the timetable of the new appointment
- Conclusion: There is some uncertainty due to the announcement
#novonordisk
#news
#deutschebank
#aktie
#aktiennews